Home / Locations / Bioluminux Naperville
Bioluminux Naperville, Illinois
About This Site
Our Naperville research site serves as our Global headquarters. It supports the greater Chicago area, as well as Phase 2–4 clinical trials across multiple therapeutic areas, including metabolic disorders, CNS, dermatology, vaccines, and many other therapeutic areas. The site is staffed by a dedicated team with deep experience in patient care and clinical operations.
With strong links to local healthcare providers and a diverse patient population, Naperville is well-positioned to meet enrolment targets quickly and deliver clean, reliable data. Sponsors benefit from our streamlined processes and commitment to quality at every stage of the trial.
Research Leadership
Orsolya Lawrence, BA (Hons) RICR, MBA(c)
Site Lead
Specialty:
Lisa Walinski, DO, Board Certified Family Medicine
Principal Investigator
Specialty:
Adeshola Ezeokoli, MD, Board Certified - Internal Medicine
Principal Investigator
Specialty:
Caroline Poku, MD, Board Certified - Internal Medicine - Endocrinology, Diabetes & Metabolism
Principal Investigator
Specialty:
Kimball Ladien, MD Boarded Certified Psychiatrist
Principal Investigator
Specialty:
Maria Malanych, MSN, APRN, FNP-BC
Sub-investigator
Specialty:
Site Facilities & Amenities
Recruiting Studies At This Location
IgA Nephropathy Study (Chronic Kidney Disease)
To evaluate if the study drug impacts the disease compared to placebo. Are you 18 years or older? Are you diagnosed with IgAN from a kidney biopsy, or are you willing to have a biopsy if needed? This study will evaluate a study drug versus placebo given every 4 weeks to people with immunoglobulin A nephropathy (IgAN) to learn if it impacts the disease.
Obesity and Type 2 Diabetes
To evaluate an investigational GLP-1 treatment for obesity and type 2 diabetes.
COPD Antiviral Research Study
To evaluate an investigational antiviral medication for reducing symptom severity and duration in adults with COPD.